StockMacro
Company, fund or insider

Help

Menu

Gabriel Brooks

Insider (Form 4 reporting owner): Chief Medical Officer CIK 1997809Name as filed: Brooks GabrielIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 21 Oct 2024, sold $337K in 7 sales (5 under a 10b5-1 plan set in advance) of Solid Biosciences.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Solid Biosciences SLDBChief Medical Officer21 Oct 202419 Oct 2026–7$337K

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After salestoo few trades4 tradestoo few trades4 tradestoo few trades3 trades

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––4$288K-$288K
2025––2$30K-$30K
2024––1$19K-$19K

Every trade

7, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
19 Oct 2026Solid Biosciences SLDBSellafter exercising options4,374$5.62$25K10b5-1 planForm 4filed 20 Oct 2026
18 Feb 2026Solid Biosciences SLDBSellafter exercising options0Not filedNot filed10b5-1 planForm 4filed 18 Feb 2026
4 Feb 2026Solid Biosciences SLDBSell12,616$6.44$81K10b5-1 planForm 4filed 6 Feb 2026
2 Feb 2026Solid Biosciences SLDBSellafter exercising options28,335$6.44$182K10b5-1 planForm 4filed 2 Feb 2026
20 Oct 2025Solid Biosciences SLDBSellafter exercising options2,895$5.96$17KNoForm 4filed 21 Oct 2025
14 Feb 2025Solid Biosciences SLDBSellafter exercising options3,256$3.96$13K10b5-1 planForm 4filed 18 Feb 2025
21 Oct 2024Solid Biosciences SLDBSellafter exercising options2,923$6.50$19KNoForm 4filed 22 Oct 2024

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.